<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089426</url>
  </required_header>
  <id_info>
    <org_study_id>CCI-08-00127</org_study_id>
    <nct_id>NCT01089426</nct_id>
  </id_info>
  <brief_title>Omegaven Treatment of Parenteral Nutrition (PN) Induced Liver Injury</brief_title>
  <official_title>Research Study of an Intravenous Fat Emulsion Comprised of Fish Oils (Omegaven) in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the hypothesis that administering intravenous fish oil, in lieu of
      intravenous soybean oil, can ameliorate the progression of PN-associated cholestatic liver
      disease in pediatric patients with elevated direct bilirubin requiring PN for more than 30
      days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the United States, patients dependent upon parenteral nutrition (PN) receive parenteral
      fat emulsions composed of soybean oils. Lipids are necessary in PN dependent patients due to
      their high caloric value and essential fatty acid content. They have been implicated in
      predisposing patients to PN associated liver disease. Phytosterols such as those contained in
      soybean oils are thought to have a deleterious effect on biliary secretion.

      Children requiring prolonged PN are at risk for developing PN associated liver disease. We
      hypothesize that although omega-6 fatty acid emulsions prevent fatty acid deficiency, they
      are not cleared in a manner similar to enteral chylomicrons and therefore accumulate in the
      liver and resulting in steatotic liver injury. We further hypothesize that a fat emulsion
      comprised of omega-3 fatty acids (i.e., fish oil) such as Omegaven™ would be beneficial in
      the management of steatotic liver injury by its inhibition of de novo lipogenesis, the
      reduction of arachidonic acid-derived inflammatory mediators, prevention of essential fatty
      acid deficiency through the presence of small amounts of arachidonic acid, and improved
      clearance of lipids from the serum. Animal studies have shown that IV fat emulsions (IFE)
      such as fish oil that are high in eicosapentaenic and docashexaaenoic acid reduce impairment
      of bile flow which is seen in cholestasis caused by conventional fat emulsions. Intravenous
      omega three fatty acids may be well tolerated and might reduce the inflammatory effect in the
      liver of prolonged PN exposure and could potentially reverse any hepatic dysfunction due to
      PN/IFE use. By administering Omegaven™ in place of conventional phytosterol/soybean fat
      emulsions we may reverse or prevent the progression of PN associated cholestasis and thus
      allow the patient to be maintained on adequate PN until they are able to ingest adequate
      nutrition enterally.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of reduction of direct bilirubin</measure>
    <time_frame>normalization of direct bilirubin: an expected average of approximately 5 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Liver Injury</condition>
  <arm_group>
    <arm_group_label>Historical controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A subset of patients previously seen, who have had at least 2 consecutive direct bilirubin levels &gt; 2 mg/dL, who depended on parenteral nutrition for at least 90 days after surgical therapy for congenital or acquired intestinal diseases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omegaven™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omegaven™</intervention_name>
    <description>1 g/kg/d of Omegaven until discontinuation of PN</description>
    <arm_group_label>Omegaven™</arm_group_label>
    <other_name>Highly refined fish oil for intravenous administration (10% Omegaven™)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Historical Controls</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>Historical controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients will be parenteral nutrition dependent and are expected to require PN for at
             least another 30 days

          -  Patients must have parenteral nutrition associated liver disease (PNALD) as defined by
             having at least 2 consecutive direct bilirubins &gt;2 mg/dl.

        Exclusion Criteria:

          -  Pregnancy

          -  Other causes of liver disease

          -  Enrollment in any other clinical trial involving an investigational agent (unless
             approved by the designated physicians on the multidisciplinary team)

          -  Direct bilirubin &lt; 2 mg/dl

          -  Allergy to any fish product, egg protein, and/or previous allergy to Omegaven

          -  Active coagulopathy characterized by on-going bleeding or acute need for clotting
             factor replacement such as FFP or cryoprecipitate to maintain homeostasis

          -  Impaired lipid metabolism as defined by serum Tg level &gt;400 at time of initiation of
             Omegaven

          -  Unstable diabetes mellitus

          -  Recent stroke/embolism, not including catheter related thrombosis, which is a common
             complication of central venous catheter.

          -  Collapse and shock

          -  Undefined coma status

          -  Untreated infection at time of initiation of Omegaven

          -  Hemodynamic instability

          -  &gt; 21 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell Merritt, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Russell Merritt, M.D., PhD</last_name>
    <phone>(323) 361-2181</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roy Leong, MHA</last_name>
    <phone>(323) 361-7877</phone>
    <email>rleong@chla.usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-6016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russell Merritt, M.D., PhD</last_name>
      <phone>323-361-2181</phone>
    </contact>
    <contact_backup>
      <last_name>Roy Leong</last_name>
      <phone>(323) 361-7877</phone>
      <email>rleong@chla.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Russell Merritt, M.D., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dudrick SJ, Wilmore DW, Vars HM, Rhoads JE. Long-term total parenteral nutrition with growth, development, and positive nitrogen balance. Surgery. 1968 Jul;64(1):134-42.</citation>
    <PMID>4968812</PMID>
  </reference>
  <reference>
    <citation>Wilmore DW, Dudrick SJ. Growth and development of an infant receiving all nutrients exclusively by vein. JAMA. 1968 Mar 4;203(10):860-4.</citation>
    <PMID>4965871</PMID>
  </reference>
  <reference>
    <citation>Mullick FG, Moran CA, Ishak KG. Total parenteral nutrition: a histopathologic analysis of the liver changes in 20 children. Mod Pathol. 1994 Feb;7(2):190-4.</citation>
    <PMID>8008742</PMID>
  </reference>
  <reference>
    <citation>Freund HR. Abnormalities of liver function and hepatic damage associated with total parenteral nutrition. Nutrition. 1991 Jan-Feb;7(1):1-5; discussion 5-6. Review.</citation>
    <PMID>1802177</PMID>
  </reference>
  <reference>
    <citation>Beath SV, Davies P, Papadopoulou A, Khan AR, Buick RG, Corkery JJ, Gornall P, Booth IW. Parenteral nutrition-related cholestasis in postsurgical neonates: multivariate analysis of risk factors. J Pediatr Surg. 1996 Apr;31(4):604-6.</citation>
    <PMID>8801324</PMID>
  </reference>
  <reference>
    <citation>Greenberg GR, Wolman SL, Christofides ND, Bloom SR, Jeejeebhoy KN. Effect of total parenteral nutrition on gut hormone release in humans. Gastroenterology. 1981 May;80(5 pt 1):988-93.</citation>
    <PMID>6781979</PMID>
  </reference>
  <reference>
    <citation>Yeh SL, Chen WJ, Huang PC. Effects of L-glutamine on induced hepatosteatosis in rats receiving total parenteral nutrition. J Formos Med Assoc. 1995 Oct;94(10):593-9.</citation>
    <PMID>8527958</PMID>
  </reference>
  <reference>
    <citation>Kubota A, Yonekura T, Hoki M, Oyanagi H, Kawahara H, Yagi M, Imura K, Iiboshi Y, Wasa K, Kamata S, Okada A. Total parenteral nutrition-associated intrahepatic cholestasis in infants: 25 years' experience. J Pediatr Surg. 2000 Jul;35(7):1049-51.</citation>
    <PMID>10917294</PMID>
  </reference>
  <reference>
    <citation>Moss RL, Das JB, Ansari G, Raffensperger JG. Hepatobiliary dysfunction during total parenteral nutrition is caused by infusate, not the route of administration. J Pediatr Surg. 1993 Mar;28(3):391-6; discussion 396-7.</citation>
    <PMID>8468653</PMID>
  </reference>
  <reference>
    <citation>Helms RA, Christensen ML, Mauer EC, Storm MC. Comparison of a pediatric versus standard amino acid formulation in preterm neonates requiring parenteral nutrition. J Pediatr. 1987 Mar;110(3):466-70.</citation>
    <PMID>3102712</PMID>
  </reference>
  <reference>
    <citation>Moss RL, Haynes AL, Pastuszyn A, Glew RH. Methionine infusion reproduces liver injury of parenteral nutrition cholestasis. Pediatr Res. 1999 May;45(5 Pt 1):664-8.</citation>
    <PMID>10231861</PMID>
  </reference>
  <reference>
    <citation>Meehan JJ, Georgeson KE. Prevention of liver failure in parenteral nutrition-dependent children with short bowel syndrome. J Pediatr Surg. 1997 Mar;32(3):473-5.</citation>
    <PMID>9094021</PMID>
  </reference>
  <reference>
    <citation>Whalen GF, Shamberger RC, Perez-Atayde A, Folkman J. A proposed cause for the hepatic dysfunction associated with parenteral nutrition. J Pediatr Surg. 1990 Jun;25(6):622-6.</citation>
    <PMID>2113578</PMID>
  </reference>
  <reference>
    <citation>Zamir O, Nussbaum MS, Bhadra S, Subbiah MT, Rafferty JF, Fischer JE. Effect of enteral feeding on hepatic steatosis induced by total parenteral nutrition. JPEN J Parenter Enteral Nutr. 1994 Jan-Feb;18(1):20-5.</citation>
    <PMID>8164298</PMID>
  </reference>
  <reference>
    <citation>Kaminski DL, Adams A, Jellinek M. The effect of hyperalimentation on hepatic lipid content and lipogenic enzyme activity in rats and man. Surgery. 1980 Jul;88(1):93-100.</citation>
    <PMID>6104363</PMID>
  </reference>
  <reference>
    <citation>Hultin M, Carneheim C, Rosenqvist K, Olivecrona T. Intravenous lipid emulsions: removal mechanisms as compared to chylomicrons. J Lipid Res. 1995 Oct;36(10):2174-84.</citation>
    <PMID>8576643</PMID>
  </reference>
  <reference>
    <citation>Qi K, Al-Haideri M, Seo T, Carpentier YA, Deckelbaum RJ. Effects of particle size on blood clearance and tissue uptake of lipid emulsions with different triglyceride compositions. JPEN J Parenter Enteral Nutr. 2003 Jan-Feb;27(1):58-64.</citation>
    <PMID>12549600</PMID>
  </reference>
  <reference>
    <citation>Nestel PJ. Effects of N-3 fatty acids on lipid metabolism. Annu Rev Nutr. 1990;10:149-67. Review.</citation>
    <PMID>2200461</PMID>
  </reference>
  <reference>
    <citation>Chen WJ, Yeh SL, Huang PC. Effects of fat emulsions with different fatty acid composition on plasma and hepatic lipids in rats receiving total parenteral nutrition. Clin Nutr. 1996 Feb;15(1):24-8.</citation>
    <PMID>16843991</PMID>
  </reference>
  <reference>
    <citation>Yeh SL, Chen WJ, Huang PC. Effects of fish oil and safflower oil emulsions on diet-induced hepatic steatosis in rats receiving total parenteral nutrition. Clin Nutr. 1996 Apr;15(2):80-3.</citation>
    <PMID>16844003</PMID>
  </reference>
  <reference>
    <citation>Kinsella JE, Lokesh B, Broughton S, Whelan J. Dietary polyunsaturated fatty acids and eicosanoids: potential effects on the modulation of inflammatory and immune cells: an overview. Nutrition. 1990 Jan-Feb;6(1):24-44; discussion 59-62. Review.</citation>
    <PMID>2135755</PMID>
  </reference>
  <reference>
    <citation>Alwayn IP, Gura K, Nosé V, Zausche B, Javid P, Garza J, Verbesey J, Voss S, Ollero M, Andersson C, Bistrian B, Folkman J, Puder M. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005 Mar;57(3):445-52. Epub 2005 Jan 19.</citation>
    <PMID>15659701</PMID>
  </reference>
  <reference>
    <citation>Van Aerde JE, Duerksen DR, Gramlich L, Meddings JB, Chan G, Thomson AB, Clandinin MT. Intravenous fish oil emulsion attenuates total parenteral nutrition-induced cholestasis in newborn piglets. Pediatr Res. 1999 Feb;45(2):202-8.</citation>
    <PMID>10022591</PMID>
  </reference>
  <reference>
    <citation>Morlion BJ, Torwesten E, Lessire H, Sturm G, Peskar BM, Fürst P, Puchstein C. The effect of parenteral fish oil on leukocyte membrane fatty acid composition and leukotriene-synthesizing capacity in patients with postoperative trauma. Metabolism. 1996 Oct;45(10):1208-13.</citation>
    <PMID>8843174</PMID>
  </reference>
  <reference>
    <citation>Grimminger F, Führer D, Papavassilis C, Schlotzer E, Mayer K, Heuer KU, Kiss L, Walmrath D, Piberhofer S, Lübbecke F, et al. Influence of intravenous n-3 lipid supplementation on fatty acid profiles and lipid mediator generation in a patient with severe ulcerative colitis. Eur J Clin Invest. 1993 Nov;23(11):706-15.</citation>
    <PMID>8307090</PMID>
  </reference>
  <reference>
    <citation>Grimminger F, Mayser P, Papavassilis C, Thomas M, Schlotzer E, Heuer KU, Führer D, Hinsch KD, Walmrath D, Schill WB, et al. A double-blind, randomized, placebo-controlled trial of n-3 fatty acid based lipid infusion in acute, extended guttate psoriasis. Rapid improvement of clinical manifestations and changes in neutrophil leukotriene profile. Clin Investig. 1993 Aug;71(8):634-43.</citation>
    <PMID>8219661</PMID>
  </reference>
  <reference>
    <citation>Mayser P, Mrowietz U, Arenberger P, Bartak P, Buchvald J, Christophers E, Jablonska S, Salmhofer W, Schill WB, Krämer HJ, Schlotzer E, Mayer K, Seeger W, Grimminger F. Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial. J Am Acad Dermatol. 1998 Apr;38(4):539-47. Erratum in: J Am Acad Dermatol 1998 Sep;39(3):421.</citation>
    <PMID>9555791</PMID>
  </reference>
  <reference>
    <citation>Heller AR, Fischer S, Rössel T, Geiger S, Siegert G, Ragaller M, Zimmermann T, Koch T. Impact of n-3 fatty acid supplemented parenteral nutrition on haemostasis patterns after major abdominal surgery. Br J Nutr. 2002 Jan;87 Suppl 1:S95-101.</citation>
    <PMID>11895160</PMID>
  </reference>
  <reference>
    <citation>Gura KM, Parsons SK, Bechard LJ, Henderson T, Dorsey M, Phipatanakul W, Duggan C, Puder M, Lenders C. Use of a fish oil-based lipid emulsion to treat essential fatty acid deficiency in a soy allergic patient receiving parenteral nutrition. Clin Nutr. 2005 Oct;24(5):839-47.</citation>
    <PMID>16029913</PMID>
  </reference>
  <reference>
    <citation>Andorsky DJ, Lund DP, Lillehei CW, Jaksic T, Dicanzio J, Richardson DS, Collier SB, Lo C, Duggan C. Nutritional and other postoperative management of neonates with short bowel syndrome correlates with clinical outcomes. J Pediatr. 2001 Jul;139(1):27-33.</citation>
    <PMID>11445790</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Los Angeles</investigator_affiliation>
    <investigator_full_name>Russell Merritt</investigator_full_name>
    <investigator_title>Medical Director of Nutrition Support and Intestinal Rehabilitation</investigator_title>
  </responsible_party>
  <keyword>Pediatric patients with Parenteral Nutrition (PN) induced Liver Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

